Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles

Journal of Controlled Release

Volumn 192, Issue , 2014, Pages 114-121

  Liu, Yang ^a   Zhu, Yan Hua ^a   Mao, Cheng Qiong ^a   Dou, Shuang ^a,b   Shen, Song ^a   Tan, Zi Bin ^a   Wang, Jun ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cationic lipid assisted nanoparticle; Cyclin dependent kinase 1; siRNA delivery; Synthetic lethality; Triple negative breast cancer

Indexed keywords

CELL DEATH; DISEASES; ENZYMES; NANOPARTICLES; POLYETHYLENE GLYCOLS;

CATIONIC LIPIDS; CYCLIN-DEPENDENT KINASE; SIRNA DELIVERY; SYNTHETIC LETHALITY; TRIPLE-NEGATIVE BREAST CANCERS;

GENE THERAPY;

CYCLIN DEPENDENT KINASE 1; DINACICLIB; LIPID; MACROGOL; MYC PROTEIN; NANOPARTICLE; POLY(ETHYLENE GLYCOL)BLOCK POLY(DEXTRO LEVO LACTIDE); POLYLACTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; DRUG CARRIER; MACROGOL DERIVATIVE; MONOMETHOXYPOLYETHYLENEGLYCOL-POLYLACTIDE BLOCK COPOLYMER; POLY(ETHYLENE GLYCOL) B POLY(DEXTRO LACTIDE)NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST EPITHELIUM; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; LETHALITY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; BREAST; CHEMISTRY; GENE THERAPY; GENETICS; METABOLISM; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; ANIMAL CELL; BREAST CANCER CELL LINE; CANCER CELL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION;

ANIMALS; BREAST; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; GENETIC THERAPY; HUMANS; MICE; NANOPARTICLES; POLYETHYLENE GLYCOLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84904989844     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.07.001     Document Type: Article

References (59)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
2. A. Bosch, P. Eroles, R. Zaragoza, J.R. Vina, and A. Lluch Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research Cancer Treat. Rev. 36 2010 206 215
3. D.S. Tan, C. Marchio, R.L. Jones, K. Savage, I.E. Smith, M. Dowsett, and J.S. Reis-Filho Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthr (Pubitemid 352009225)
4. J.S. Reis-Filho, and A.N. Tutt Triple negative tumours: a critical review Histopathology 52 2008 108 118 (Pubitemid 350265179)
5. M. Clarke, R. Collins, C. Davies, J. Godwin, R. Gray, and R. Peto Early breast cancer trialists collaborative, Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467 (Pubitemid 28227036)
6. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 5 2005 341 354 (Pubitemid 40637826)
7. J.E. Uhm, Y.H. Park, S.Y. Yi, E.Y. Cho, Y. La Choi, S.J. Lee, M.J. Park, S.H. Lee, H.J. Jun, J.S. Ahn, W.K. Kang, K. Park, and Y.H. Im Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy Int. J. Cancer 124 2009 1457 1462
8. R. Torrisi, A. Balduzzi, R. Ghisini, A. Rocca, L. Bottiglieri, F. Giovanardi, P. Veronesi, A. Luini, L. Orlando, G. Viale, A. Goldhirsch, and M. Colleoni Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel Cancer Chemother. Pharmacol. 62 2008 667 672
9. L. Verlinden, I. Vanden Bempt, G. Eelen, M. Drijkoningen, I. Verlinden, K. Marchal, C. De Wolf-Peeters, M.R. Christiaens, L. Michiels, R. Bouillon, and A. Verstuyf The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas Cancer Res. 67 2007 6574 6581 (Pubitemid 47105501)
10. K. Do, and A.P. Chen Molecular pathways: targeting PARP in cancer treatment Clin. Cancer Res. 19 2013 977 984
11. F.C. Geyer, M. Lacroix-Triki, K. Savage, M. Arnedos, M.B. Lambros, A. MacKay, R. Natrajan, and J.S. Reis-Filho beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation Mod. Pathol. 24 2011 209 231
12. P. Bouwman, A. Aly, J.M. Escandell, M. Pieterse, J. Bartkova, H. van der Gulden, S. Hiddingh, M. Thanasoula, A. Kulkarni, Q. Yang, B.G. Haffty, J. Tommiska, C. Blomqvist, R. Drapkin, D.J. Adams, H. Nevanlinna, J. Bartek, M. Tarsounas, S. Ganesan, and J. Jonkers 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Nat. Struct. Mol. Biol. 17 2010 688 695
13. E. Alli, V.B. Sharma, P. Sunderesakumar, and J.M. Ford Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase Cancer Res. 69 2009 3589 3596
14. J. O'Shaughnessy, C. Osborne, J.E. Pippen, M. Yoffe, D. Patt, C. Rocha, I.C. Koo, B.M. Sherman, and C. Bradley Iniparib plus chemotherapy in metastatic triple-negative breast cancer N. Engl. J. Med. 364 2011 205 214
15. D. Horiuchi, L. Kusdra, N.E. Huskey, S. Chandriani, M.E. Lenburg, A.M. Gonzalez-Angulo, K.J. Creasman, A.V. Bazarov, J.W. Smyth, S.E. Davis, P. Yaswen, G.B. Mills, L.J. Esserman, and A. Goga MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition J. Exp. Med. 209 2012 679 696
16. N. Meyer, and L.Z. Penn MYC - timeline reflecting on 25 years with MYC Nat. Rev. Cancer 8 2008 976 990
17. W.G. Kaelin The concept of synthetic lethality in the context of anticancer therapy Nat. Rev. Cancer 5 2005 689 698
18. D. Yang, H. Liu, A. Goga, S. Kim, M. Yuneva, and J.M. Bishop Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase Proc. Natl. Acad. Sci. U. S. A. 107 2010 13836 13841
19. Y. Wang, I.H. Engels, D.A. Knee, M. Nasoff, Q.L. Deveraux, and K.C. Quon Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway Cancer Cell 5 2004 501 512 (Pubitemid 38610251)
20. A. Sierra, X. Castellsague, A. Escobedo, A. Moreno, T. Drudis, and A. Fabra Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T-1 human breast carcinomas Breast Cancer Res. Treat. 54 1999 39 45 (Pubitemid 29209916)
21. J.J. Molenaar, M.E. Ebus, D. Geerts, J. Koster, F. Lamers, L.J. Valentijn, E.M. Westerhout, R. Versteeg, and H.N. Caron Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells Proc. Natl. Acad. Sci. U. S. A. 106 2009 12968 12973
22. A. Goga, D. Yang, A.D. Tward, D.O. Morgan, and J.M. Bishop Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC Nat. Med. 13 2007 820 827 (Pubitemid 47038193)
23. C. Scholl, S. Froehling, I.F. Dunn, A.C. Schinzel, D.A. Barbie, S.Y. Kim, S.J. Silver, P. Tamayo, R.C. Wadlow, S. Ramaswamy, K. Doehner, L. Bullinger, P. Sandy, J.S. Boehm, D.E. Root, T. Jacks, W.C. Hahn, and D.G. Gilliland Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells Cell 137 2009 821 834
24. D.A. Barbie, P. Tamayo, J.S. Boehm, S.Y. Kim, S.E. Moody, I.F. Dunn, A.C. Schinzel, P. Sandy, E. Meylan, C. Scholl, S. Froehling, E.M. Chan, M.L. Sos, K. Michel, C. Mermel, S.J. Silver, B.A. Weir, J.H. Reiling, Q. Sheng, P.B. Gupta, R.C. Wadlow, H. Le, S. Hoersch, B.S. Wittner, S. Ramaswamy, D.M. Livingston, D.M. Sabatini, M. Meyerson, R.K. Thomas, E.S. Lander, J.P. Mesirov, D.E. Root, D.G. Gilliland, T. Jacks, and W.C. Hahn Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 462 2009 108 U122
25. Y. Wang, V.N. Ngo, M. Marani, Y. Yang, G. Wright, L.M. Staudt, and J. Downward Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells Oncogene 29 2010 4658 4670
26. M. Puyol, A. Martin, P. Dubus, F. Mulero, P. Pizcueta, G. Khan, C. Guerra, D. Santamaria, and M. Barbacid A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma Cancer Cell 18 2010 63 73
27. L. Soucek, J. Whitfield, C.P. Martins, A.J. Finch, D.J. Murphy, N.M. Sodir, A.N. Karnezis, L.B. Swigart, S. Nasi, and G.I. Evan Modelling Myc inhibition as a cancer therapy Nature 455 2008 679 683
28. M. Malumbres, P. Pevarello, M. Barbacid, and J.R. Bischoff CDK inhibitors in cancer therapy: what is next? Trends Pharmacol. Sci. 29 2008 16 21
29. G.J. Hannon, and J.J. Rossi Unlocking the potential of the human genome with RNA interference Nature 431 2004 371 378 (Pubitemid 39265678)
30. M.E. Davis, J.E. Zuckerman, C.H.J. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen, J.D. Heidel, and A. Ribas Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 U1140
31. P. Kumar, H.-S. Ban, S.S. Kim, H. Wu, T. Pearson, D.L. Greiner, A. Laouar, J. Yao, V. Haridas, K. Habiro, Y.G. Yang, J.H. Jeong, K.Y. Lee, Y.H. Kim, S.W. Kim, M. Peipp, G.H. Fey, N. Manjunath, L.D. Shultz, S.K. Lee, and P. Shankar T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice Cell 134 2008 577 586
32. D. Peer, E.J. Park, Y. Morishita, C.V. Carman, and M. Shimaoka Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target Science 319 2008 627 630 (Pubitemid 351197066)
33. C. Raoul, T. Abbas-Terki, J.C. Bensadoun, S. Guillot, G. Haase, J. Szulc, C.E. Henderson, and P. Aebischer Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS Nat. Med. 11 2005 423 428 (Pubitemid 40562333)
34. A.P. McCaffrey, H. Nakai, K. Pandey, Z. Huang, F.H. Salazar, H. Xu, S.F. Wieland, P.L. Marion, and M.A. Kay Inhibition of hepatitis B virus in mice by RNA interference Nat. Biotechnol. 21 2003 639 644 (Pubitemid 36638090)
35. S. Hu-Lieskovan, J.D. Heidel, D.W. Bartlett, M.E. Davis, and T.J. Triche Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma Cancer Res. 65 2005 8984 8992 (Pubitemid 41377390)
36. E.W. Song, P.C. Zhu, S.K. Lee, D. Chowdhury, S. Kussman, D.M. Dykxhoorn, Y. Feng, D. Palliser, D.B. Weiner, P. Shankar, W.A. Marasco, and J. Lieberman Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat. Biotechnol. 23 2005 709 717 (Pubitemid 41716361)
37. J. Yano, K. Hirabayashi, S. Nakagawa, T. Yamaguchi, M. Nogawa, I. Kashimori, H. Naito, H. Kitagawa, K. Ishiyama, T. Ohgi, and T. Irimura Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer Clin. Cancer Res. 10 2004 7721 7726 (Pubitemid 39557537)
38. A. Muratovska, and M.R. Eccles Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells FEBS Lett. 558 2004 63 68 (Pubitemid 38167411)
39. J.O. McNamara, E.R. Andrechek, Y. Wang, K.D. Viles, R.E. Rempel, E. Gilboa, B.A. Sullenger, and P.H. Giangrande Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras Nat. Biotechnol. 24 2006 1005 1015 (Pubitemid 44215395)
40. T.M. Sun, J.Z. Du, Y.D. Yao, C.Q. Mao, S. Dou, S.Y. Huang, P.Z. Zhang, K.W. Leong, E.W. Song, and J. Wang Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression ACS Nano 5 2011 1483 1494
41. Y.D. Yao, T.M. Sun, S.Y. Huang, S. Dou, L. Lin, J.N. Chen, J.B. Ruan, C.Q. Mao, F.Y. Yu, M.S. Zeng, J.Y. Zang, Q. Liu, F.X. Su, P. Zhang, J. Lieberman, J. Wang, and E. Song Targeted delivery of PLK1-siRNA by scFv suppresses her2(+) breast cancer growth and metastasis Sci. Transl. Med. 4 2012
42. X.Z. Yang, S. Dou, T.M. Sun, C.Q. Mao, H.X. Wang, and J. Wang Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy J. Control. Release 156 2011 203 211
43. X.Z. Yang, J.Z. Du, S. Dou, C.Q. Mao, H.Y. Long, and J. Wang Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery ACS Nano 6 2012 771 781
44. C.Q. Mao, J.Z. Du, T.M. Sun, Y.D. Yao, P.Z. Zhang, E.W. Song, and J. Wang A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy Biomaterials 32 2011 3124 3133
45. A. Cheng, M. Li, Y. Liang, Y. Wang, L. Wong, C. Chen, A.V. Vlassov, and S. Magdaleno Stem-loop RT-PCR quantification of siRNAs in vitro and in vivo Oligonucleotides 19 2009 203 208
46. X.Q. Liu, C.Y. Sun, X.Z. Yang, and J. Wang Polymeric-micelle-based nanomedicine for siRNA delivery Part. Part. Syst. Charact. 30 2013 211 228
47. M. Eilers, and R.N. Eisenman Myc's broad reach Gene Dev. 22 2008 2755 2766
48. E.M. Blackwood, and R.N. Eisenman Max-a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc Science 251 1991 1211 1217 (Pubitemid 21926213)
49. B. Amati, M.W. Brooks, N. Levy, T.D. Littlewood, G.I. Evan, and H. Land Oncogenic activity of the C-Myc protein requires dimerization with Max Cell 72 1993 233 245 (Pubitemid 23044938)
50. D.E. Ayer, L. Kretzner, and R.N. Eisenman Mad-a heterodimeric partner for Max that antagonizes Myc transcriptional activity Cell 72 1993 211 222 (Pubitemid 23044936)
51. S. Pelengaris, T. Littlewood, M. Khan, G. Elia, and G. Evan Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion Mol. Cell 3 1999 565 577 (Pubitemid 29268440)
52. R. Jaenisch, and R. Young Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming Cell 132 2008 567 582 (Pubitemid 351253686)
53. N.S. Gray, L. Wodicka, A. Thunnissen, T.C. Norman, S.J. Kwon, F.H. Espinoza, D.O. Morgan, G. Barnes, S. LeClerc, L. Meijer, S.H. Kim, D.J. Lockhart, and P.G. Schultz Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 281 1998 533 538 (Pubitemid 28357362)
54. V. Schreiber, F. Dantzer, J.-C. Ame, and G. de Murcia Poly(ADP-ribose): novel functions for an old molecule Nat. Rev. Mol. Cell Biol. 7 2006 517 528 (Pubitemid 44036457)
55. G.I. Shapiro Cyclin-dependent kinase pathways as targets for cancer treatment J. Clin. Oncol. 24 2006 1770 1783 (Pubitemid 46628473)
56. M. Malumbres, and M. Barbacid To cycle or not to cycle: a critical decision in cancer Nat. Rev. Cancer 1 2001 222 231 (Pubitemid 33741897)
57. D. Santamaria, C. Barriere, A. Cerqueira, S. Hunt, C. Tardy, K. Newton, J.F. Caceres, P. Dubus, M. Malumbres, and M. Barbacid Cdk1 is sufficient to drive the mammalian cell cycle Nature 448 2007 811 818
58. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer-chemotherapy-mechanism of tumoritropic accumulation of preteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
59. J.T. Marques, and B.R.G. Williams Activation of the mammalian immune system by siRNAs Nat. Biotechnol. 23 2005 1399 1405 (Pubitemid 41679392)